The FDA has issued a series of warning letters to compounding pharmacies producing semaglutide and tirzepatide, signaling an aggressive regulatory posture toward the compounded GLP-1 market. These enforcement actions have significant implications for patients currently using compounded medications. Here is what you need to understand.
What Are FDA Warning Letters?
An FDA warning letter is a formal communication from the agency to a company indicating that the FDA has found significant violations of federal law or regulations. Warning letters are not penalties themselves but rather notices that violations have been identified and that failure to correct them may result in enforcement action, including seizure of products, injunctions, or criminal prosecution.
Recent Warning Letters to GLP-1 Compounders
Between late 2025 and early 2026, the FDA issued warning letters to more than a dozen compounding pharmacies producing semaglutide and tirzepatide. The violations cited in these letters include producing compounded drugs that are essentially copies of commercially available FDA-approved medications, using drug substances not produced by FDA-registered facilities, making false or misleading claims about the safety and efficacy of compounded products, and failing to meet current good manufacturing practice standards.
The Legal Framework
The legality of compounding GLP-1 medications hinges primarily on the FDA drug shortage list. Under the Federal Food, Drug, and Cosmetic Act, compounding pharmacies can produce copies of commercially available drugs when those drugs are on the FDA shortage list. When semaglutide was listed as in shortage, compounding was legally permissible. As the shortage status changes, the legal basis for compounding becomes more contested.
This creates a dynamic regulatory environment. Semaglutide has been added to and removed from the shortage list multiple times. Each change in status affects the legality of ongoing compounding activities. For real-time updates on shortage list changes and FDA enforcement actions, GLP-1 Watchdog's FDA alert tracker provides regularly updated monitoring of these developments.
What the Warning Letters Specifically Cite
Several common themes appear across the warning letters:
- Use of semaglutide salt forms: The FDA contends that semaglutide sodium and semaglutide acetate are different substances from the semaglutide base used in Ozempic and Wegovy. Compounders argue these are pharmacologically equivalent.
- Quality control deficiencies: Some pharmacies were cited for inadequate sterility testing, improper storage conditions, or failure to verify the identity and potency of active ingredients.
- Misleading marketing: Several pharmacies were cited for implying that their compounded products were equivalent to or interchangeable with FDA-approved brand-name medications.
- Prescribing irregularities: Some compounding operations were linked to telehealth platforms that issued prescriptions without adequate medical evaluations.
Impact on Patients
If you are currently using compounded semaglutide or tirzepatide, these warning letters do not mean you need to immediately stop your medication. However, they should prompt you to take several steps:
- Verify that your compounding pharmacy has not received a warning letter by checking the FDA's warning letter database
- Ask your pharmacy about their compliance status and quality control measures
- Discuss alternative medication options with your prescribing physician
- Begin exploring insurance coverage or patient assistance programs for brand-name medications as a contingency
- Do not stockpile medication from pharmacies that may face enforcement action
Industry Response
The compounding industry has responded through legal challenges, with several pharmacies filing lawsuits contesting the FDA's authority to restrict compounding of drugs on and off the shortage list. Industry trade groups argue that compounded GLP-1 medications fill a critical access gap for patients who cannot afford brand-name drugs. The outcome of these legal challenges will significantly shape the future of the compounded GLP-1 market.
What Comes Next
Regulatory experts expect the FDA to continue escalating enforcement against compounders producing GLP-1 medications, particularly those that have received warning letters and have not demonstrated corrective action. The timeline for formal enforcement actions is uncertain, but patients using compounded medications should develop contingency plans. For a comprehensive comparison of both brand-name and compounded GLP-1 providers, visit GLP-1 Watchdog, which tracks the regulatory status of providers.
Our Assessment
The FDA warning letters reflect legitimate safety and quality concerns. While the economic access argument for compounded GLP-1 medications has merit, quality and safety cannot be compromised. Patients should use this moment to evaluate their compounding pharmacy's quality credentials, maintain a relationship with a knowledgeable prescriber, and explore all available options for obtaining medication through regulated channels.